Final Agenda

19th meeting of the Committee for Risk Assessment

29 November – 2 December 2011
Helsinki, Finland

29 November: starts at 9:00
2 December: ends at 13:00

Item 1 – Welcome & Apologies

Item 2 – Adoption of the Agenda

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Adoption of the minutes of the RAC-18

Item 5 – Administrative issues and information items

5.1 Report on RAC-18 action points, written procedures and other ECHA bodies

5.2 Update of the form on annual declaration of interests (Annex 2 to the RAC Rules of Procedure)
Item 6 – Requests under Article 77 (3)(c)

6.1 Gallium arsenide

For discussion and possible adoption

Item 7 – CLH

7.1 CLH Dossiers

- a. Pitch, coal tar, high temp. (CTPHT) - adopted via written procedure, no further discussion
- b. N-ethyl-2-pyrrolidone (NEP)
- c. Nitrobenzene
- d. Octadecylamine
- e. (Z)-octadec-9-enylamine
- f. Amines, hydrogenated tallow alkyl
- g. Amines, coco alkyl
- h. Amines, tallow alkyl
- i. Ammoniumpentadecafluorooctanoate (APFO)
- j. Perfluorooctanic acid (PFOA)
- k. Aluminium phosphide
- l. Trimagnesium diphosphide

For discussion and possible adoption

- m. p-tert-butylphenol
- n. 4-vinylcyclohexene (VCH)
- o. Cymoxanil
- p. Proquinazid
- q. Dioctyltin bis(2-Ethylhexyl mercaptoacetate)
- r. Amidosulfuron

For discussion

7.2 Appointment of RAC (co-) rapporteurs for CLH dossiers

RAC/19/2011/36
Room document
For agreement

7.3 General and procedural CLH issues

- a. State of play of the submitted CLH dossiers

For information

Item 8 – Restrictions
8.1  Restriction Annex XV dossiers
   a.  Phthalates – first draft opinion  
      
8.2  General restriction issues
   a.  Update on intended restriction dossiers  
   b.  Update on the review of the restriction process including the project on improving the quality of incoming restriction reports
      
Item 9 – Authorisation

9.1  Evaluation of applications by RAC and SEAC & Capacity building
   a.  Common approach of RAC and SEAC in opinion development on Applications for Authorisation
   b.  Discussion
   c.  Overview of the capacity building programme
   d.  Use of registration data, possibilities, limitations, quality issues with emphasis on exposure scenarios
   e.  Demonstration of the use of dissemination portals for databases on chemicals
   f.  Discussion
      
9.2  Appointment of RAC rapporteurs for substances listed in Annex XIV (if relevant)
      
Item 10 – Guidance issues

10.1 Update on guidance activities including on guidance on the application of the CLP criteria
      
Item 11 – Update on stakeholder participation in the work of RAC
   (Closed session)
      
RAC/19/2011/37
   Room document
   For discussion

RAC/19/2011/38
   Room document
   For agreement

RAC/19/2011/39
   Room document
   For agreement
Item 12 – Any other business

12.1 Information on the BauA project on the evaluation of exposure models.
RAC/19/2011/40
Room document
For information

Item 13– Main conclusions and Action Points of RAC-19

Table with main conclusions and action points from RAC-19
For adoption
PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-19

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Some discussions may require a closed session

Tuesday, 29 November: Morning Session

Item 1 – Welcome & Apologies
Item 2 – Adoption of the Agenda
Item 3 – Declarations of conflicts of interest to the Agenda
Item 4 – Adoption of the minutes of the RAC-18
Item 5 – Administrative issues and information items
Item 6 – Requests under Article 77 (3)(c)
   6.1 Gallium arsenide
Item 7 – CLH
   7.1 CLH Dossiers - For discussion and possible adoption
       b) N-ethyl-2-pyrrolidone (NEP)
       c) Nitrobenzene
       d) Octadecylamine
       e) (Z)-octadec-9-enylamine
       f) Amines, hydrogenated tallow alkyl
       g) Amines, coco alkyl
       h) Amines, tallow alkyl
       i) Ammoniumpentadecafluorooctanoate (APFO)
       j) Perfluorooctanoic acid (PFOA)
       k) Aluminium phosphide
       l) Trimagnesium diphosphide

Tuesday, 29 November: Afternoon Session

7.1 CLH Dossiers - For discussion
   m) p-tert-butylphenol
   n) 4-vinylcyclohexene (VCH)
   o) Cymoxanil
   p) Proquinazid
   q) Dioctyltin bis(2-Ethylhexyl mercaptoacetate)
   r) Amidosulfuron

7.3 General and procedural CLH issues
   a. State of play of the submitted CLH dossiers
Wednesday, 30 November: Morning Session
Item 10 – Guidance issues
Optional – Item 6 – Requests under Article 77 (3)(c)
  6.1 Gallium arsenide
Optional – Item 7 – CLH
  7.1 CLH Dossiers for discussion and possible adoption: discussion on CLH dossiers for adoption as needed.

Wednesday, 30 November: Afternoon Session
Optional – Item 6 – Requests under Article 77 (3)(c)
  6.1 Gallium arsenide
Optional – Item 7 – CLH
  7.1 CLH Dossiers for discussion and possible adoption: discussion on CLH dossiers for adoption as needed.

Thursday 1 December: Morning Session
Item 8 – Restrictions
  8.1 Restriction Annex XV dossiers
    a. Phthalates – first draft opinion
  8.2 General restriction issues
    a. Update on intended restriction dossiers
    b. Update on the review of the restriction process including the project on improving the quality of incoming restriction reports

Optional – Item 6 – Requests under Article 77 (3)(c)
  6.1 Gallium arsenide
Optional – Item 7 – CLH
  7.1 CLH Dossiers for discussion and possible adoption: discussion on CLH dossiers for adoption as needed.
Item 9 – Authorisation
  9.1 Evaluation of applications by RAC and SEAC & Capacity building
    a) Common approach of RAC and SEAC in opinion development on Applications for Authorisation
    b) Discussion

Thursday 1 December: Afternoon Session
Item 9 – Authorisation
  9.1 Evaluation of applications by RAC and SEAC & Capacity building
    c) Overview of the capacity building programme
    d) Use of registration data, possibilities, limitations, quality issues with emphasis on exposure scenarios
    e) Demonstration of the use of dissemination portals for databases on
chemicals
f) Discussion

Optional – Item 6 – Requests under Article 77 (3)(c)
6.1 Gallium arsenide

Friday 2 December: Morning Session

Optional – Item 6 – Requests under Article 77 (3)(c)
6.1 Gallium arsenide

Item 7 – CLH

Optional – 7.1 CLH Dossiers for discussion and possible adoption:
second discussion on CLH dossiers for adoption as needed.

7.2 Appointment of RAC (co-) rapporteurs for CLH dossiers.

Item 9 – Authorisation

9.2 Appointment of RAC rapporteurs for substances listed in Annex XIV (if relevant)

Item 11 – Update on stakeholder participation in the work of RAC (Closed Session)

Item 12 – Any other business

Item 13 – Main conclusions and Action Points of RAC-18